Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-8068 + Adebrelimab + Bevacizumab in Advanced HCC
NCT05444088Phase 2Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Aug 2022
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of CS1002 in hepatocellular carcinoma (HCC), sponsored by Suzhou Suncadia Biopharmaceutical. Started Aug 2022; status: recruiting.
02
Drugs
CS1002
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05444088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05444088.